Introduction

　　Established in 1989, the Department of Hematology at Shenzhen Second People’s Hospital is one of the first two hematology specialties in Shenzhen. With 35 years of development, it has become a leading hematological diagnosis and treatment center in Guangdong Province. The department is recognized as a Guangdong Provincial Key Clinical Specialty, a Shenzhen Key Medical Discipline, and serves as the Chair Unit of the Hematology Division of the Shenzhen Medical Association.

　　Specialty Features

　　The department includes one specialized laboratory, the Shenzhen Hematology Research Institute, founded in 1990; one outpatient clinic; and two inpatient wards with a total of 72 beds, including 10 laminar flow transplant beds. Annually, it handles over 12,000 outpatient visits and admits more than 3,000 inpatients.

　　To provide specialized and high-quality care, the department has established subspecialties in hematopoietic stem cell transplantation, acute leukemia, lymphoma, plasma cell disorders (multiple myeloma), myeloproliferative neoplasms (MPN), and bleeding disorders such as hemophilia. The Hematopoietic Stem Cell Transplantation Center, which performed Shenzhen’s first bone marrow transplant in 1990, has since conducted nearly 1,000 hematopoietic stem cell transplants, including allogeneic sibling, haploidentical, unrelated donor, and autologous transplants. The center is also a certified unrelated hematopoietic stem cell collection unit for the China Marrow Donor Program and has been repeatedly recognized as an advanced unit for its contributions to stem cell collection since 2001.

　　The subspecialties for acute leukemia, lymphoma, and plasma cell disorders focus on integrating precision medicine with a comprehensive treatment platform. This platform includes chemotherapy, targeted therapy, immunotherapy, hematopoietic stem cell transplantation, CAR-T cell therapy, GCP clinical trials for new drugs, and palliative care. Personalized treatments are tailored to patient-specific factors such as age and genetic characteristics, significantly improving cure rates for malignant hematologic diseases and extending survival times for elderly patients.

　　The specialized outpatient clinics for hematopoietic stem cell transplantation, MPN, and hemophilia provide standardized, professional care for chronic myeloid leukemia, myelofibrosis, and bleeding disorders. These clinics emphasize long-term follow-up, addressing both the physical and mental health of patients while improving their quality of life.